Clinical trial

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

NCT06939166

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-06-17

PhaseEARLY_PHASE1

Study timeline

Study start (actual)2025-06-17Date precision: day

Registry last updated2025-12-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Neuromyelitis Optica Spectrum Disordersunresolved

Myasthenia Gravisunresolved

Multiple Sclerosisunresolved

Chronic Inflammatory Demyelinating Polyradiculoneuropathyunresolved

Autoimmune Encephalitisunresolved

Interventions

UCAR T-cellDRUG

Sponsors & collaborators

Tianjin Huanhu Hospitallead sponsor

Shanghai Xiniao Biotech Co., Ltd.collaborator

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06939166 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.